Clinical trial data suggest the IL-6-targeted drug clazakizumab ameliorates the symptoms of psoriatic arthritis (PsA), in particular the musculoskeletal manifestations of the disease. Could this new treatment hold promise for a certain subgroup of patients with PsA?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The use of leukocytes’ secretome to individually target biological therapy in autoimmune arthritis: a case report
Clinical and Translational Medicine Open Access 05 June 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Haroon, M., Kirby, B. & FitzGerald, O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann. Rheum. Dis. 72, 736–740 (2013).
Kane, D., Stafford, L., Bresnihan, B. & FitzGerald, O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis experience. Rheumatology (Oxford) 42, 1460–1468 (2003).
Mease, P. et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase 2b study of adults with active psoriatic arthritis. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39700 (2016).
Glintborg, B. et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 65, 1213–1223 (2013).
Fagerli, K. M. et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann. Rheum. Dis. 72, 1840–1844 (2013).
Partsch, G. et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24, 518–523 (1997).
Alenius, G. M., Eriksson, C. & Rantapaa Dahlqvist, S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin. Exp. Rheumatol. 27, 120–123 (2009).
Spadaro, A. et al. Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin. Exp. Rheumatol. 14, 413–416 (1996).
van Kuijk, A. W., Reinders-Blankert, P., Smeets, T. J., Dijkmans, B. A. & Tak, P. P. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann. Rheum. Dis. 65, 1551–1557 (2006).
Coates, L. C. et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386, 2489–2498 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares that he has received consultancy, speaker's honoraria and research support from Abbvie, BMS, Celgene, Eli Lilly, Janssen, Novartis and Pfizer.
Rights and permissions
About this article
Cite this article
FitzGerald, O. IL-6 blockade in psoriatic arthritis — a new therapeutic option?. Nat Rev Rheumatol 12, 318–319 (2016). https://doi.org/10.1038/nrrheum.2016.84
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.84
This article is cited by
-
The use of leukocytes’ secretome to individually target biological therapy in autoimmune arthritis: a case report
Clinical and Translational Medicine (2019)
